The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-(5,6-bis(4-fluorophenyl)-1,2,4-triazin-3-yl)-1H-1,2,4-triazole-5(4H)-thione ID: ALA5288780
Max Phase: Preclinical
Molecular Formula: C17H10F2N6S
Molecular Weight: 368.37
This compound is available for customization.
Associated Items:
Names and Identifiers Canonical SMILES: Fc1ccc(-c2nnc(-n3cn[nH]c3=S)nc2-c2ccc(F)cc2)cc1
Standard InChI: InChI=1S/C17H10F2N6S/c18-12-5-1-10(2-6-12)14-15(11-3-7-13(19)8-4-11)22-23-16(21-14)25-9-20-24-17(25)26/h1-9H,(H,24,26)
Standard InChI Key: BLCDNQFHRAVBPF-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 29 0 0 0 0 0 0 0 0999 V2000
1.0241 0.0142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1991 0.0142 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1991 -0.6969 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1991 -1.4082 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0241 -1.4082 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4224 -2.0910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.2189 -2.0910 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.6457 -1.4082 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.2189 -0.6969 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4224 -0.6969 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.4423 -1.4082 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-0.1991 -2.0910 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.9957 -2.0910 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-1.3939 -1.4082 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9957 -0.6969 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.2190 -1.4082 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.6742 -0.7538 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4466 0.0142 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
-3.4423 -0.9814 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.4423 -1.8064 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-2.6742 -2.0625 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.1991 0.6970 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.1991 1.4082 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.0241 1.4082 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4224 0.6970 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.4224 2.0910 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
2 1 2 0
3 2 1 0
3 4 2 0
4 5 1 0
5 6 2 0
7 6 1 0
8 7 2 0
9 8 1 0
10 9 2 0
5 10 1 0
8 11 1 0
4 12 1 0
12 13 2 0
14 13 1 0
14 15 2 0
3 15 1 0
14 16 1 0
17 16 1 0
17 18 2 0
17 19 1 0
19 20 1 0
21 20 2 0
21 16 1 0
2 22 1 0
22 23 2 0
23 24 1 0
24 25 2 0
25 1 1 0
24 26 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 368.37Molecular Weight (Monoisotopic): 368.0656AlogP: 3.73#Rotatable Bonds: 3Polar Surface Area: 72.28Molecular Species: NEUTRALHBA: 6HBD: 1#RO5 Violations: ┄HBA (Lipinski): 6HBD (Lipinski): 1#RO5 Violations (Lipinski): ┄CX Acidic pKa: 7.27CX Basic pKa: ┄CX LogP: 4.29CX LogD: 3.96Aromatic Rings: 4Heavy Atoms: 26QED Weighted: 0.56Np Likeness Score: -1.49
References 1. Cascioferro S, Parrino B, Spanò V, Carbone A, Montalbano A, Barraja P, Diana P, Cirrincione G.. (2017) An overview on the recent developments of 1,2,4-triazine derivatives as anticancer compounds., 142 [PMID:28851503 ] [10.1016/j.ejmech.2017.08.009 ]